Vitamin D3 supplementation and treatment outcomes in patients with depression (D3-vit-dep)

Jens Peter Hansen*, Manan Pareek, Allan Hvolby, Anne Schmedes, Tomas Toft, Erik Dahl, Connie Thurøe Nielsen

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review

84 Downloads (Pure)

Abstract

Objective: To examine whether vitamin D supplementation in patients with depression would result in a reduction in Hamilton D-17 depression score (primary outcome) at 3 and 6 months compared to controls and to explore the correlations between serum vitamin D and symptoms of depression, wellbeing, systolic blood pressure, and waist circumference. In this outpatient multicentre study conducted between 2010 and 2013, patients, 18-65 years old, diagnosed with mild to severe depression were randomly assigned to receive D supplementation 70 micrograms daily or placebo on top of standard treatment. Participants, care givers and those assessing the outcomes were blinded to group assignment. Results: At baseline, 23 patients had a normal 25(OH)D level, 22 had insufficiency (< 25 nmol/L), and 17 had deficiency (25-50 nmol/L). No significant reduction in depression was seen after vitamin D supplementation compared to placebo at Hamilton (18.4-18.0; p = 0.73 at 12 weeks). Vitamin D supplementation did not provide a reduction in symptom score among patients with depression. Trial registration The trial was registered in the National Board of Health (EudraCT: 2011-002585-20) and in ClinicalTrials.Gov (NCT01390662).

Original languageEnglish
Article number203
JournalBMC Research Notes
Volume12
Number of pages6
ISSN1756-0500
DOIs
Publication statusPublished - 3. Apr 2019

Fingerprint

Cholecalciferol
Vitamin D
Placebos
Blood pressure
Caregivers
Multicenter Studies
Outpatients
Health
Serum

Keywords

  • Depression
  • Double-blind method
  • Drug therapy
  • Randomised controlled trial
  • Vitamin D deficiency
  • Severity of Illness Index
  • Vitamin D Deficiency/drug therapy
  • Double-Blind Method
  • Humans
  • Middle Aged
  • Male
  • Treatment Outcome
  • Depression/drug therapy
  • Young Adult
  • Cholecalciferol/administration & dosage
  • Adolescent
  • Adult
  • Female
  • Aged
  • Dietary Supplements
  • Vitamins/administration & dosage

Cite this

@article{496507a26de84f71a8eb81cf84873943,
title = "Vitamin D3 supplementation and treatment outcomes in patients with depression (D3-vit-dep)",
abstract = "Objective: To examine whether vitamin D supplementation in patients with depression would result in a reduction in Hamilton D-17 depression score (primary outcome) at 3 and 6 months compared to controls and to explore the correlations between serum vitamin D and symptoms of depression, wellbeing, systolic blood pressure, and waist circumference. In this outpatient multicentre study conducted between 2010 and 2013, patients, 18-65 years old, diagnosed with mild to severe depression were randomly assigned to receive D supplementation 70 micrograms daily or placebo on top of standard treatment. Participants, care givers and those assessing the outcomes were blinded to group assignment. Results: At baseline, 23 patients had a normal 25(OH)D level, 22 had insufficiency (< 25 nmol/L), and 17 had deficiency (25-50 nmol/L). No significant reduction in depression was seen after vitamin D supplementation compared to placebo at Hamilton (18.4-18.0; p = 0.73 at 12 weeks). Vitamin D supplementation did not provide a reduction in symptom score among patients with depression. Trial registration The trial was registered in the National Board of Health (EudraCT: 2011-002585-20) and in ClinicalTrials.Gov (NCT01390662).",
keywords = "Depression, Double-blind method, Drug therapy, Randomised controlled trial, Vitamin D deficiency, Severity of Illness Index, Vitamin D Deficiency/drug therapy, Double-Blind Method, Humans, Middle Aged, Male, Treatment Outcome, Depression/drug therapy, Young Adult, Cholecalciferol/administration & dosage, Adolescent, Adult, Female, Aged, Dietary Supplements, Vitamins/administration & dosage",
author = "Hansen, {Jens Peter} and Manan Pareek and Allan Hvolby and Anne Schmedes and Tomas Toft and Erik Dahl and Nielsen, {Connie Thur{\o}e}",
year = "2019",
month = "4",
day = "3",
doi = "10.1186/s13104-019-4218-z",
language = "English",
volume = "12",
journal = "BMC Research Notes",
issn = "1756-0500",
publisher = "BioMed Central",

}

Vitamin D3 supplementation and treatment outcomes in patients with depression (D3-vit-dep). / Hansen, Jens Peter; Pareek, Manan; Hvolby, Allan; Schmedes, Anne; Toft, Tomas; Dahl, Erik; Nielsen, Connie Thurøe.

In: BMC Research Notes, Vol. 12, 203, 03.04.2019.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Vitamin D3 supplementation and treatment outcomes in patients with depression (D3-vit-dep)

AU - Hansen, Jens Peter

AU - Pareek, Manan

AU - Hvolby, Allan

AU - Schmedes, Anne

AU - Toft, Tomas

AU - Dahl, Erik

AU - Nielsen, Connie Thurøe

PY - 2019/4/3

Y1 - 2019/4/3

N2 - Objective: To examine whether vitamin D supplementation in patients with depression would result in a reduction in Hamilton D-17 depression score (primary outcome) at 3 and 6 months compared to controls and to explore the correlations between serum vitamin D and symptoms of depression, wellbeing, systolic blood pressure, and waist circumference. In this outpatient multicentre study conducted between 2010 and 2013, patients, 18-65 years old, diagnosed with mild to severe depression were randomly assigned to receive D supplementation 70 micrograms daily or placebo on top of standard treatment. Participants, care givers and those assessing the outcomes were blinded to group assignment. Results: At baseline, 23 patients had a normal 25(OH)D level, 22 had insufficiency (< 25 nmol/L), and 17 had deficiency (25-50 nmol/L). No significant reduction in depression was seen after vitamin D supplementation compared to placebo at Hamilton (18.4-18.0; p = 0.73 at 12 weeks). Vitamin D supplementation did not provide a reduction in symptom score among patients with depression. Trial registration The trial was registered in the National Board of Health (EudraCT: 2011-002585-20) and in ClinicalTrials.Gov (NCT01390662).

AB - Objective: To examine whether vitamin D supplementation in patients with depression would result in a reduction in Hamilton D-17 depression score (primary outcome) at 3 and 6 months compared to controls and to explore the correlations between serum vitamin D and symptoms of depression, wellbeing, systolic blood pressure, and waist circumference. In this outpatient multicentre study conducted between 2010 and 2013, patients, 18-65 years old, diagnosed with mild to severe depression were randomly assigned to receive D supplementation 70 micrograms daily or placebo on top of standard treatment. Participants, care givers and those assessing the outcomes were blinded to group assignment. Results: At baseline, 23 patients had a normal 25(OH)D level, 22 had insufficiency (< 25 nmol/L), and 17 had deficiency (25-50 nmol/L). No significant reduction in depression was seen after vitamin D supplementation compared to placebo at Hamilton (18.4-18.0; p = 0.73 at 12 weeks). Vitamin D supplementation did not provide a reduction in symptom score among patients with depression. Trial registration The trial was registered in the National Board of Health (EudraCT: 2011-002585-20) and in ClinicalTrials.Gov (NCT01390662).

KW - Depression

KW - Double-blind method

KW - Drug therapy

KW - Randomised controlled trial

KW - Vitamin D deficiency

KW - Severity of Illness Index

KW - Vitamin D Deficiency/drug therapy

KW - Double-Blind Method

KW - Humans

KW - Middle Aged

KW - Male

KW - Treatment Outcome

KW - Depression/drug therapy

KW - Young Adult

KW - Cholecalciferol/administration & dosage

KW - Adolescent

KW - Adult

KW - Female

KW - Aged

KW - Dietary Supplements

KW - Vitamins/administration & dosage

U2 - 10.1186/s13104-019-4218-z

DO - 10.1186/s13104-019-4218-z

M3 - Journal article

VL - 12

JO - BMC Research Notes

JF - BMC Research Notes

SN - 1756-0500

M1 - 203

ER -